193 related articles for article (PubMed ID: 8280289)
41. Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel.
Brown ML; Zha CC; Van Dyke CC; Brown GB; Brouillette WJ
J Med Chem; 1999 May; 42(9):1537-45. PubMed ID: 10229624
[TBL] [Abstract][Full Text] [Related]
42. The synthesis, stability and biological activity of bis-intercalating bis-daunomycin hydrazones.
Phillips DR; Baguley BC; Brownlee RT; Cacioli P; Chandler CJ; Kyratzis I; Reiss JA; Scourides PA
Drug Des Deliv; 1990 Mar; 5(3):203-19. PubMed ID: 1670502
[TBL] [Abstract][Full Text] [Related]
43. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
44. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
45. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Bhongade BA; Gadad AK
Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
[TBL] [Abstract][Full Text] [Related]
46. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.
Li LH; DeKoning TF; Kelly RC; Krueger WC; McGovren JP; Padbury GE; Petzold GL; Wallace TL; Ouding RJ; Prairie MD
Cancer Res; 1992 Sep; 52(18):4904-13. PubMed ID: 1516047
[TBL] [Abstract][Full Text] [Related]
47. New Research for Quinazoline-2,4-diones as HPPD Inhibitors Based on 2D-MLR and 3D-QSAR Models.
Fu Y; Sun YN; Cao HF; Yi KH; Zhao LX; Li JZ; Ye F
Comb Chem High Throughput Screen; 2017; 20(9):748-759. PubMed ID: 28637410
[TBL] [Abstract][Full Text] [Related]
48. Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide.
Rewcastle GW; Atwell GJ; Chambers D; Baguley BC; Denny WA
J Med Chem; 1986 Apr; 29(4):472-7. PubMed ID: 3959026
[TBL] [Abstract][Full Text] [Related]
49. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
Debnath AK
J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and comparative molecular field analysis (CoMFA) of antitumor 3-arylisoquinoline derivatives.
Cho WJ; Kim EK; Park MJ; Choi SU; Lee CO; Cheon SH; Choi BG; Chung BH
Bioorg Med Chem; 1998 Dec; 6(12):2449-58. PubMed ID: 9925301
[TBL] [Abstract][Full Text] [Related]
51. A 3D-QSAR Study on the Antitrypanosomal and Cytotoxic Activities of Steroid Alkaloids by Comparative Molecular Field Analysis.
Nnadi CO; Althaus JB; Nwodo NJ; Schmidt TJ
Molecules; 2018 May; 23(5):. PubMed ID: 29738470
[TBL] [Abstract][Full Text] [Related]
52. Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Spicer JA; Gamage SA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1997 Jun; 40(12):1919-29. PubMed ID: 9191970
[TBL] [Abstract][Full Text] [Related]
53. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
54. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
Chaube U; Bhatt H
Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
[TBL] [Abstract][Full Text] [Related]
55. 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
Krapcho AP; Petry ME; Getahun Z; Landi JJ; Stallman J; Polsenberg JF; Gallagher CE; Maresch MJ; Hacker MP; Giuliani FC
J Med Chem; 1994 Mar; 37(6):828-37. PubMed ID: 8145234
[TBL] [Abstract][Full Text] [Related]
56. Molecular modeling of triazine type MDR modulators using CoMFA and CoMSIA approaches.
Tsakovska IM; Pajeva IK
SAR QSAR Environ Res; 2002; 13(3-4):487-98. PubMed ID: 12184389
[TBL] [Abstract][Full Text] [Related]
57. Comparative molecular field analysis of quinine derivatives used as chiral selectors in liquid chromatography: 3D QSAR for the purposes of molecular design of chiral stationary phases.
Schefzick S; Lämmerhofer M; Lindner W; Lipkowitz KB; Jalaie M
Chirality; 2000 Nov; 12(10):742-50. PubMed ID: 11054833
[TBL] [Abstract][Full Text] [Related]
58. Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells.
Badiner GJ; Hamilton RD; Li LH; Bhuyan BK
Invest New Drugs; 1987; 5(3):219-29. PubMed ID: 3667160
[TBL] [Abstract][Full Text] [Related]
59. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
Shih KC; Lin CY; Chi HC; Hwang CS; Chen TS; Tang CY; Hsiao NW
J Chem Inf Model; 2012 Jan; 52(1):146-55. PubMed ID: 22142286
[TBL] [Abstract][Full Text] [Related]
60. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
